MX2019004549A - Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos. - Google Patents

Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.

Info

Publication number
MX2019004549A
MX2019004549A MX2019004549A MX2019004549A MX2019004549A MX 2019004549 A MX2019004549 A MX 2019004549A MX 2019004549 A MX2019004549 A MX 2019004549A MX 2019004549 A MX2019004549 A MX 2019004549A MX 2019004549 A MX2019004549 A MX 2019004549A
Authority
MX
Mexico
Prior art keywords
inhibitor
ssao
vap
disorders
combinations
Prior art date
Application number
MX2019004549A
Other languages
English (en)
Spanish (es)
Inventor
Mark Michael
Klein Thomas
Williams Mayoux Eric
Rippmann Joerg
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019004549A publication Critical patent/MX2019004549A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019004549A 2016-10-19 2017-10-16 Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos. MX2019004549A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16194572 2016-10-19
PCT/EP2017/076300 WO2018073154A1 (en) 2016-10-19 2017-10-16 Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof

Publications (1)

Publication Number Publication Date
MX2019004549A true MX2019004549A (es) 2019-06-12

Family

ID=57178303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004549A MX2019004549A (es) 2016-10-19 2017-10-16 Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.

Country Status (14)

Country Link
US (1) US20210212968A1 (enExample)
EP (1) EP3528800A1 (enExample)
JP (1) JP2019531320A (enExample)
KR (1) KR20190070956A (enExample)
CN (1) CN109843279A (enExample)
AU (1) AU2017344882A1 (enExample)
BR (1) BR112019005930A2 (enExample)
CA (1) CA3041169A1 (enExample)
CL (1) CL2019000935A1 (enExample)
EA (1) EA201990951A1 (enExample)
IL (1) IL265989A (enExample)
MX (1) MX2019004549A (enExample)
PH (1) PH12019500845A1 (enExample)
WO (1) WO2018073154A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CA3114166A1 (en) * 2018-09-28 2020-04-02 Acucela Inc. Inhibitors of vap-1
MX2021003559A (es) 2018-09-28 2021-08-24 Acucela Inc Inhibidores de vap-1.
JP7414230B2 (ja) * 2018-11-09 2024-01-16 国立大学法人 琉球大学 抗血液悪性腫瘍薬
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) * 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
AU2020377093B2 (en) 2019-10-29 2026-02-26 Eccogene Inc. SSAO inhibitors and use thereof
IL296816A (en) * 2020-03-25 2022-11-01 Terns Inc Treatment of respiratory disorders
US20210379040A1 (en) * 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN113893256A (zh) * 2020-07-06 2022-01-07 诺未科技（北京）有限公司 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
CA3193057A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
WO2022183289A1 (en) * 2021-03-04 2022-09-09 The Governors Of The University Of Alberta The use of empagliflozin for the treatment of ulcerative colitis and crohn's disease
CN119013027A (zh) * 2021-11-11 2024-11-22 拓臻制药公司 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
EP4429637A1 (en) * 2021-11-11 2024-09-18 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100591585B1 (ko) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
EP1344780A4 (en) 2000-11-30 2004-01-28 Kissei Pharmaceutical GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
ATE431830T1 (de) 2000-12-28 2009-06-15 Kissei Pharmaceutical Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
MXPA04009229A (es) 2002-03-22 2004-11-26 Kissei Pharmaceutical Cristales derivados de glucopiranosiloxibencil benceno.
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
ES2363941T3 (es) 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
CN103030617A (zh) 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US7846945B2 (en) 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
PT2183263E (pt) 2007-07-26 2012-01-11 Lexicon Pharmaceuticals Inc Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
RS56990B1 (sr) 2007-09-10 2018-05-31 Janssen Pharmaceutica Nv Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
CN101917845A (zh) 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
US20110014284A1 (en) 2009-02-13 2011-01-20 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
SG2014012553A (en) 2009-04-16 2014-05-29 Taisho Pharmaceutical Co Ltd Pharmaceutical compositions
PT2486029E (pt) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
EA020798B1 (ru) 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
AU2013255103B2 (en) * 2012-05-02 2016-09-29 Syntara Limited Substituted 3-haloallylamine inhibitors of SSAO and uses thereof

Also Published As

Publication number Publication date
PH12019500845A1 (en) 2019-12-02
AU2017344882A1 (en) 2019-03-28
US20210212968A1 (en) 2021-07-15
JP2019531320A (ja) 2019-10-31
EP3528800A1 (en) 2019-08-28
WO2018073154A1 (en) 2018-04-26
KR20190070956A (ko) 2019-06-21
BR112019005930A2 (pt) 2019-06-11
CA3041169A1 (en) 2018-04-26
IL265989A (en) 2019-06-30
EA201990951A1 (ru) 2019-11-29
CL2019000935A1 (es) 2019-08-09
CN109843279A (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2021002321A (es) Nuevos metodos.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
EP4292588A3 (en) Administration of deuterated cftr potentiators
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX377629B (es) Composiciones farmacéuticas tópicas.
MX381475B (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
WO2016133903A3 (en) Combination therapy for cancer treatment
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2019013862A (es) Terapia de combinacion.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
EP3590338A3 (en) Medical treatments based on anamorelin
MX2020001727A (es) Terapia de combinacion.
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
WO2015035410A8 (en) Cancer therapy